CA Market News
6日前
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 MillionJune 3, 2026 6:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - June 3, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, is pleased to announce that, further to its news releases of May 11 and June 1, 2026, it has completed an oversubscribed non-brokered private placement (the "Offering") through the issuance of 18,143,700 common shares (the "Offered Shares") at a price of C$0.50 per Offered Share for gross proceeds of C$9,071,850. All securities issued in connection with the Offering are subject to a four-month plus one day hold period ending October 2, 2026. The Offering has received conditional acceptance from the TSX Venture Exchange and remains subject to final acceptance. In connection with the Offering, the Company paid certain qualified finders: (i) a cash finder's fee equal to 7% of the gross proceeds raised from subscribers introduced by such finders, and (ii) non-transferable finder's options equal to 7% of the Offered Shares issued to such subscribers. Each finder's option entitles the holder to acquire one common share at a price of C$0.60 per share for a period of three years. In total, the Company paid C$561,529.50 in finder's fees and issued 780,059 finder's options. An independent director of the Company participated in the Offering and acquired 150,000 Offered Shares. The issuance to such insider constitutes a "related party transaction" under Multilateral Instrument 61-101 ("MI 61-101"). The Company relied on exemptions from the formal valuation and minority shareholder approval requirements in accordance with MI 61-101 and applicable policies of the TSX Venture Exchange. Net proceeds from the Offering will be used to advance the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2a clinical study in Leigh syndrome spectrum, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate purposes. In connection with the Offering, the Company engaged Bloom Burton Securities Inc. as a financial and strategic advisor on a non-exclusive basis. Bloom Burton provided advisory services to the Company in respect of the oversubscribed Offering. The Company paid Bloom Burton Securities Inc. a cash fee of C$50,000 for its advisory services. Bloom Burton Securities Inc. does not own any securities of the Company.About ThiogenesisBased in San Diego, California, Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a novel once-daily, controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development. The Company is also planning to conduct a Phase 2a clinical study in Leigh syndrome spectrum disorders.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward Looking StatementsSome statements contained in this news release are forward-looking information within the meaning of Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as plans, expects, is expected, budget, scheduled, estimates, forecasts, intends, anticipates, believes or variations of such words and phrases including negative or grammatical variations or statements that certain actions, events or results may, could, would, might or will be taken, occur or be achieved or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual facts to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. While we may elect to update these estimates at any time, we do not undertake to update any estimate at any particular time or in response to any event.Neither the TSX Venture Exchange nor its Regulation Services Provider as that term is defined in the policies of the TSX Venture Exchange nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this news release.This news release is not an offer of securities for sale in the United States. The securities may not be offered or sold in the United States absent registration or an exemption from registration under U.S. Securities Act of 1933, as amended - the U.S. Securities Act. The Company has not registered and will not register the securities under the U.S. Securities Act. The Company does not intend to engage in a public offering of their securities in the United States.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299857 Original: Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
CA Market News
1週前
Thiogenesis Upsizes Non-Brokered Private Placement of Common SharesJune 1, 2026 2:49 PM
NewsfileSan Diego, California--(Newsfile Corp. - June 1, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, today announced that, due to strong investor demand, it has increased the size of its previously announced non-brokered private placement (the "Offering") (see the Company's news release dated May 11, 2026) from 16 million to approximately 18 million common shares at a price of $0.50 per Common Share of the Company for gross proceeds of approximately $9 million.The Offering has received conditional acceptance from the TSX Venture Exchange. Closing is expected to occur later this week, subject to final acceptance by the TSX Venture Exchange and customary closing conditions.Net proceeds from the Offering will be used to advance the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2a clinical study in Leigh syndrome spectrum, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate purposes. About ThiogenesisBased in San Diego, California, Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also advancing research and clinical work in primary mitochondrial diseases, initially focused on Leigh syndrome spectrum disorders.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward-Looking StatementsSome statements contained in this news release are forward-looking information within the meaning of Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as plans, expects, is expected, budget, scheduled, estimates, forecasts, intends, anticipates, believes or variations of such words and phrases including negative or grammatical variations or statements that certain actions, events or results may, could, would, might or will be taken, occur or be achieved or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual facts to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. While we may elect to update these estimates at any time, we do not undertake to update any estimate at any particular time or in response to any event.Neither the TSX Venture Exchange nor its Regulation Services Provider as that term is defined in the policies of the TSX Venture Exchange nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this news release.This news release is not an offer of securities for sale in the United States. The securities may not be offered or sold in the United States absent registration or an exemption from registration under U.S. Securities Act of 1933, as amended - the U.S. Securities Act. The Company has not registered and will not register the securities under the U.S. Securities Act. The Company does not intend to engage in a public offering of their securities in the United States.NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299682 Original: Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
CA Market News
4週前
Thiogenesis Announces Non-Brokered Private PlacementMay 11, 2026 9:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - May 11, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, announced today that it will undertake a non-brokered private placement (the "Offering") of up to 16,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share for gross proceeds of $8 million.This Offering is subject to the approval of the TSX Venture Exchange (the "Exchange"). The Company anticipates closing of the Offering by the end of May subject to receipt of all necessary regulatory approvals. Upon issuance, the Offered Shares will be subject to a four-month and one day hold period pursuant to securities laws in Canada and, where applicable, Exchange policies.In connection with the Offering, the Company may pay finder's fees to eligible persons in compliance with applicable securities laws and Exchange policies. The proceeds of the financing will be used to support the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2 clinical study in Leigh syndrome, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate purposes.About ThiogenesisBased in San Diego, California, Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to offer improved tolerability and dosing compared with existing therapies. The company is advancing TTI-0102 toward a pivotal Phase 3 clinical trial in nephropathic cystinosis and is supporting clinical development in inherited mitochondrial diseases, following completion of a Phase 2 programme in MELAS and the initiation of a Phase 2 clinical study in Leigh syndrome.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward Looking StatementsThis news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as forward-looking statements) within the meaning of Canadian securities laws including, without limitation, statements with respect to: the Company undertaking a non-brokered private placement to raise up to $8 million at a price of $0.50 per Common Share; the Offering being subject to the approval of the TSX Venture Exchange; the Company anticipating closing the Offering as soon as practicable; that the Shares (if sold) will be subject to a four-month and one day hold period; that the Company may pay finder's fees in connection with the Offering; the proceeds (if Shares are sold) from the Offering will be used for MELAS clinical trial expenses, the creation and purchase of additional TTI-0102 for future clinical trials. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons, as such term is defined in Regulation S under the Securities Act ("Regulation S"), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act.NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/296807 Original: Thiogenesis Announces Non-Brokered Private Placement
CA Market News
2月前
Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 16, 2026 9:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - April 16, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based prodrugs designed as precursors to thiol-active compounds such as cysteamine, today announced that management will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in Toronto, Canada.Presentation Details:Date: Wednesday, April 22, 2026
Time: 1:30-2:00 p.m. ET
Location: Room 104 A
Presenters: Brook Riggins, CFA, Director and Chief Financial Officer, and Patrice Rioux, M.D., Ph.D., Chief Executive Officer and Co-FounderThe presentation will provide an overview of Thiogenesis Therapeutics and its clinical-stage development programs, including its late-stage lead program in nephropathic cystinosis and expansion into mitochondrial disease indications, including Leigh syndrome.About Bloom Burton & Co.Bloom Burton & Co. is a leading Canadian investment bank focused exclusively on the healthcare sector. The firm's annual healthcare investor conference brings together public and private healthcare companies with institutional investors and industry participants to discuss clinical progress, emerging science and investment opportunities.About Thiogenesis TherapeuticsThiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company with operations based in San Diego, California. The Company is developing sulfur-containing prodrugs designed as precursors to previously approved thiol-active compounds, with a focus on serious pediatric diseases with significant unmet medical need. Thiogenesis' lead product candidate, TTI-0102, is a late-stage program being advanced toward a Phase 3 clinical trial in nephropathic cystinosis. In addition, the Company is pursuing the potential expansion of its thiol-based platform into mitochondrial diseases, including Leigh syndrome and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke (MELAS), as well as other metabolic indications.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward Looking StatementsThis news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as forward-looking statements) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. (OTCQX: OTCM) accepts responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292731
Original: Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
CA Market News
4月前
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program UpdateFebruary 2, 2026 9:00 AM
NewsfileSan Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University and Children's Healthcare of Atlanta.The IIS will evaluate Thiogenesis' lead product candidate, TTI-0102, a next-generation cysteamine-based prodrug, in patients with nephropathic cystinosis to further characterize once-daily dosing, tolerability, and white blood cell (WBC) cystine control across a representative patient population. Data generated from the study are expected to support dose optimization and inform the Company's planned Phase 3 pivotal program.Dr. Greenbaum serves as Chief of Pediatric Nephrology at Children's Healthcare of Atlanta and Professor of Pediatrics at Emory University School of Medicine. He has served as a principal investigator in multiple cystinosis clinical programs and sits on the scientific and medical advisory boards of leading cystinosis patient organizations. His clinical site previously participated in the development of delayed-release cysteamine therapy, providing direct continuity with current standards of care.TTI-0102: Designed to Address Limitations of Current Cysteamine TherapiesCystinosis requires lifelong cystine-depleting therapy; however, currently approved cysteamine products, Cystagon® and Procysbi®, are associated with frequent dosing, gastrointestinal intolerance, and adherence challenges that can limit long-term disease control.TTI-0102 is a novel cysteamine-based disulfide prodrug designed to deliver sustained cysteamine exposure with lower peak plasma concentrations, enabling the potential for once-daily oral dosing.Across clinical development programs, TTI-0102 has demonstrated:Sustained 24-hour cysteamine exposure with weight-based dosingLower peak-related gastrointestinal adverse events compared to fixed dosing approachesTarget cysteamine exposure achieved at approximately half the daily cysteamine base dose used with existing therapiesA dual biological profile supporting cystine depletion and intracellular antioxidant pathways, including glutathione and taurine, consistent with cysteamine biologyImportantly, dosing and tolerability insights from Thiogenesis' Phase 2 MELAS program have directly informed cystinosis development strategy, supporting refined, weight-based dosing designed to optimize exposure while minimizing adverse events.Phase 3 Development and Regulatory PathwayThiogenesis is preparing to initiate scale-up of the manufacturing process for a newly patented salt formulation of TTI-0102, which is required to produce sufficient clinical material to support formal stability testing. Stability testing of the new salt formulation is expected to be conducted in parallel with finalization of the Company's Investigational New Drug (IND) application for cystinosis.Upon completion of these activities, the Company plans to initiate a Phase 3 pivotal, non-inferiority study comparing TTI-0102 to an approved cysteamine therapy under FDA's 505(b)(2) regulatory pathway.The planned Phase 3 study is expected to leverage:WBC cystine concentration as a well-validated surrogate endpointA non-inferiority design versus standard-of-care cysteamine therapySimplified dosing and improved tolerability as key secondary and patient-reported outcomesGiven the well-established regulatory precedent in cystinosis and the sensitivity of WBC cystine as a biomarker, Thiogenesis believes this approach represents an efficient and well-defined path toward registration."This investigator-initiated study allows us to evaluate TTI-0102 in a real-world cystinosis population under the leadership of one of the most experienced investigators in the field," said Dr. Patrice Rioux, Chief Executive Officer of Thiogenesis Therapeutics. "We have spent years working alongside the cystinosis community and deeply understand the burden current therapies place on patients and families. TTI-0102 was engineered to simplify daily treatment while maintaining the biochemical efficacy patients depend on, and we are excited about its potential to offer a better-tolerated option that could meaningfully improve adherence and quality of life."About Nephropathic CystinosisNephropathic cystinosis is a rare, autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, leading to toxic intracellular cystine accumulation and progressive multi-organ damage. Without disease-modifying therapy, patients develop renal Fanconi syndrome, growth failure, and progression to end-stage renal disease.Cystinosis affects an estimated 2,000–2,500 patients worldwide, representing a global market opportunity of over $300 million. While cysteamine therapy slows disease progression, tolerability and adherence challenges remain a significant unmet medical need. About TTI-0102TTI-0102 is a sulfur-based disulfide prodrug consisting of two cysteamine molecules and one molecule of pantothenic acid (Vitamin B5). Following oral administration, metabolic activation delivers sustained cysteamine exposure with reduced peak-related toxicity, enabling once-daily dosing. TTI-0102 is currently in clinical development for MELAS, Leigh syndrome, pediatric MASH, and nephropathic cystinosis.About Thiogenesis TherapeuticsThiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company with operations based in San Diego, CA. The Company is publicly traded on the TSX Venture Exchange and in the U.S. on the OTCQX. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol-active compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Thiogenesis' lead product candidate, TTI-0102 has an active Phase 2 clinical trial in Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS"), an IND-cleared Phase 2a clinical trial planned in Leigh syndrome spectrum, a Phase 2 clinical trial planned in pediatric Metabolic Dysfunction-Associated Steatohepatitis ("MASH") and a Phase 3 clinical trial planned in nephropathic cystinosis.For further information, please contact:Brook Riggins, Director and CFO
Email: info @vingForward-Looking StatementsThis news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as forward-looking statements) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. (OTCQX: OTCM) accepts responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282105
Original: Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update